What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Gene
The scientist’s investigation covers issues in Internal medicine, Oncology, Lung cancer, Cancer and Cancer research.
The concepts of her Internal medicine study are interwoven with issues in Gastroenterology and Surgery.
Her Oncology research is multidisciplinary, incorporating elements of Biomarker, Carboplatin, Clinical trial and Biopsy.
Her Lung cancer research incorporates elements of Targeted therapy and Pharmacology.
Her Cancer research includes elements of Blockade, Receptor tyrosine kinase and Drug resistance.
Vassiliki A. Papadimitrakopoulou combines subjects such as Immune checkpoint, Cell, Epidermal growth factor receptor, Carcinogenesis and Immunology with her study of Cancer research.
Her most cited work include:
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (1344 citations)
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study (798 citations)
- The BATTLE Trial: Personalizing Therapy for Lung Cancer (668 citations)
What are the main themes of her work throughout her whole career to date?
Vassiliki A. Papadimitrakopoulou spends much of her time researching Internal medicine, Oncology, Lung cancer, Cancer research and Cancer.
Her Chemotherapy, Phases of clinical research, Carboplatin and Radiation therapy study in the realm of Internal medicine interacts with subjects such as In patient.
Her research in Oncology intersects with topics in Pembrolizumab and Clinical trial.
Her Lung cancer research is multidisciplinary, relying on both Targeted therapy and Immunotherapy.
Her biological study spans a wide range of topics, including Mutant, Immune system, KRAS, Lung and Adenocarcinoma.
Her Cancer study integrates concerns from other disciplines, such as Disease, Dysplasia, Pharmacology and Bioinformatics.
She most often published in these fields:
- Internal medicine (60.86%)
- Oncology (54.00%)
- Lung cancer (30.29%)
What were the highlights of her more recent work (between 2018-2021)?
- Internal medicine (60.86%)
- Oncology (54.00%)
- Lung cancer (30.29%)
In recent papers she was focusing on the following fields of study:
Her primary areas of study are Internal medicine, Oncology, Lung cancer, Cancer research and Phases of clinical research.
Her Oncology study combines topics from a wide range of disciplines, such as Pembrolizumab, Nivolumab, Ipilimumab, Immunotherapy and Carboplatin.
Her study looks at the intersection of Carboplatin and topics like Pemetrexed with Osimertinib and Hazard ratio.
Vassiliki A. Papadimitrakopoulou has included themes like Durvalumab, Cancer, Targeted therapy and Confidence interval in her Lung cancer study.
The study incorporates disciplines such as Immune system and non-small cell lung cancer in addition to Cancer research.
Her work in Phases of clinical research tackles topics such as Docetaxel which are related to areas like Locally advanced and Progression-free survival.
Between 2018 and 2021, her most popular works were:
- Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. (116 citations)
- 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer (105 citations)
- Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. (62 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Internal medicine, Oncology, Lung cancer, Immunotherapy and Adverse effect are her primary areas of study.
Internal medicine is represented through her Pembrolizumab, Carboplatin, Clinical endpoint, Pemetrexed and non-small cell lung cancer research.
Her Oncology research includes elements of Regimen, Immune checkpoint inhibitors, Nivolumab, Ipilimumab and Radiation therapy.
Her Lung cancer research focuses on Targeted therapy and how it relates to Chemoimmunotherapy, Cancer research and Immune system.
Her biological study deals with issues like Discontinuation, which deal with fields such as Intensive care medicine, Blockade, Drug development, Clinical study design and Erlotinib.
While the research belongs to areas of Adverse effect, she spends her time largely on the problem of Rash, intersecting her research to questions surrounding Gefitinib.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
